杨爽，李碧澄，王妍（综述），田野（审校）. 特殊人群的他汀类药物应用[J]. 中国急救医学, 2016, 36(7): 661-666.
YANG Shuang, LI Bi-cheng, WANG Yan, TIAN Ye. Statin use in special populations. Chinese Journal of Critical Care Medicine, 2016, 36(7): 661-666.
［1］ Sarah L, Gary W, Robert C, et al. Blood cholesterol and vascular mortality by age,sex,and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths［J］. Lancet, 2007, 370（370）:1829-1839.
［2］ Updesh B, Mukesh S, Param S, et al. Effects of statins on progression of coronary artery disease as measured by intravascular ultrasound［J］. J Clin Hypertens, 2011,13（7）:492-496.
［3］ Qing L, Song-Bai D, Shuang X, et al. Impact of intensive statin use on the level of inflammation and platelet activation in stable angina after percutaneous coronary intervention: a clinical study［J］. Med Clin, 2013, 140（12）:532-536.
［4］ Nielsen SF, Nordestgaard BG. Negative statin- related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality:a nationwide prospective cohort study［J］. Eur Heart J, 2016,37（11）:908-916.
［5］ Mosca L, Mochari- Greenberger H, Dolor RJ, et al. Twelve- year follow-up of American women’sawareness of cardiovascular disease risk and barriers to heart health［J］. Circ Cardiovasc Qual Outcomes, 2010, 3（2）:120-127.
［6］ Yang W, Xiao J, Yang Z, et al. Serum lipids and lipoproteins in Chinese men and women［J］. Circulation, 2012,125（18）:2212-2221.
［7］ Bhattacharjee S, Findley PA, Sambamoorthi U. Understanding Gender Differences in Statin Use among Elderly Medicare Beneficiaries［J］. Drugs Aging, 2012,29（12）:971-980.
［8］ Virani SS, Woodard LCD, Ramsey DJ, et al. Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease［J］. Am J Cardiol, 2015, 115（1）:21-26.
［9］ Katsiki N, Banach M. Statin use and risk of diabetes mellitus in postmenopausal women［J］. Clin Lipidol, 2012,7（3）:267-270.
［10］ Bukkapatnam RN, Gabler NB, Lewis WR. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta- analysis［J］. Preventive Cardiol, 2010,13（2）:84-90.
［11］ Ginsberg HN, Elam MB, Lovato LC, et al. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus［J］. N Engl J Med,2010, 362（17）:1563-1574.
［12］ Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials［J］. Lancet, 2015,385（9976）:1397-1405.
［13］ Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin（JUPITER）and meta-analysis of women
from primary prevention trials［J］. Circulation, 2010,121（9）:1069-1077.
［14］ Grundy SM. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia［J］. J Clin Lipidol, 2013,7（6）:561-565.
［15］ Strandberg TE, Laura K, Alpo V. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review［J］.JAMA, 2014,312（11）:1136-1144.
［16］ Gianluigi S, Gotto AM, Stefania P, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis［J］. J Am Coll Cardiol, 2013,62（22）:2090-2099.
［17］ Ridker PM, Eleanor D, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein［J］. New Engl J Med, 2008,359（21）:534.
［18］ James S, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease（PROSPER）: a randomised controlled trial. Commentary［J］. Lancet, 2002,360（2）:1623-1630.
［19］ Rabar S, Harker M, O'Flynn N, et al. Lipid modification and car⁃diovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance［J］. BMJ, 2014,349:g4356.
［20］ Ganda OP. Deciphering cholesterol treatment guidelines: a clinician's perspective［J］. JAMA, 2015, 313（2）:605-614.
［21］ Naveed S, David P, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta- analysis of randomised statin trials［J］. Lancet, 2010, 375（9716）:735-742.
［22］ David P, Paul W, Murphy SA, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis［J］. JAMA, 2011, 305（24）:2556-2564.
［23］ Swerdlow DI, David P, Kuchenbaecker KB, et al. HMG- coenzyme A reductase inhibition, type 2 diabetes, and bodyweight:evidence from genetic analysis and randomised trials［J］. Lancet, 2015, 385（14）:351-361.
［24］ Koh KK, Quon MJ, Han SH. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients［J］. Atherosclerosis, 2009, 204（2）:483-490.
［25］ Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients ［J］. J Atheroscleros Thromb,2005, 12（2）:111-119.
［26］ Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4（SLC2A4）: implications in glycaemic control［J］. Diabetologia,2006, 49（8）:1881-1892.
［27］ Henriksbo BD, Lau TC, Cavallari JF, et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance［J］.Diabetes, 2014, 63（11）:3742-3747.
［28］ Jacobson TA, Ito MK, Maki KC, et al. National Lipid association recommendations for patient- centered management of dyslipidemia: part 1-full report［J］. J Clin Lipidol, 2015, 9（2）:129-169.
［29］ Fellstr MBC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis［J］.New Engl J Med, 2009, 360（14）:1395-1407.
［30］ Geng Q, Ren J, Song J, et al. Meta- analysis of the effect of statins on renal function［J］. Am J Cardiol, 2014, 114（4）:562-570.
［31］ Jacobson TA. Statin Safety: Lessons from new drug applications for marketed statins［J］. Am J Cardiol, 2006, 97（8）:44C-51C.
［32］ Colin B, Landray MJ, Christina R, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease（study of heart and renal protection）: a randomised placebo- controlled trial［J］. Lancet, 2011, 377（9784）: 2181-2192.
［33］ Han YL, Zhu GY, Xu B, et al. Short-term statin therapy for prevention of contrast induced-acute kidney injury in patients with diabetes and chronic kidney disease［J］. Chin Med J（Engl）,2015,128（6）:784-789.
［34］ Tonelli M, Wanner C. Kidney disease:improving global outcomes lipid guideline development work group members.lipid management in chronic kidney disease: synopsis of the kidney disease:improving global outcomes 2013 clinical practice guideline［J］.Ann Intern Med, 2014,160（3）：182-189.
［35］ Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals［J］. J Hepatol,2015, 63（3）:705-712.
［36］ Tolosa L, Carmona A, Castell JV, et al. High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins［J］. Arch Toxicol, 2015, 89（10）:1847-1860.
［37］ Bays H, Cohen DE, Chalasani N, et al. An assessment by the statin liver safety task force: 2014 update［J］. J Clin Lipid,2014, 8（3）:S47-S57.
［38］ Stroes ES, Thompson PD, Alberto C, et al. Statin- associated muscle symptoms: impact on statin therapy- European atherosclerosis society consensus panel statement on assessment, aetiology and management［J］. Eur Heart J, 2015, 36（17）:1012-1022.
［39］ Ito MK, Maki KC, Brinton EA, et al. Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study［J］. J Clin Lipidol, 2014, 8（1）:69-76.
［40］ Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors［J］. Neuromuscul Disord, 2014, 24（1）:4-15.
［41］ Stroes ES, Thompson PD, Alberto C, et al. Statin- associated muscle symptoms: impact on statin therapy- European atherosclerosis society consensus panel statement on assessment, aetiology and management［J］. Eur Heart J, 2015, 36（17）:1012-1022.
［42］ Mospan CM. Are statins protective or harmful to cognitive function［J］. JAAPA, 2016, 29（1）:11-12.
［43］ Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallelgroup trial［J］. J Am Coll Cardiol, 2013, 62（13）:1154-1162.
［44］ Leander K, Mälarstig A, Van't Hooft FM, et al. Circulating PCSK9 predicts future risk of cardiovascular events indepen⁃dently of established risk factors［J］. Circulation, 2016,133（13）:1230-1239.
